MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Vascular Biogenics Ltd Company Profile (NASDAQ:VBLT)

Consensus Ratings for Vascular Biogenics Ltd (NASDAQ:VBLT) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $16.50 (257.92% upside)

Analysts' Ratings History for Vascular Biogenics Ltd (NASDAQ:VBLT)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016HC WainwrightInitiated CoverageBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Roth CapitalReiterated RatingBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016Piper JaffrayReiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015OppenheimerReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2015Deutsche BankBoost Price Target$12.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Vascular Biogenics Ltd (NASDAQ:VBLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/13/2016Q1($0.21)($0.21)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/29/2016Q4($0.32)($0.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.19)($0.29)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.19)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.19)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015($0.24)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014($0.41)($4.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Vascular Biogenics Ltd (NASDAQ:VBLT)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Vascular Biogenics Ltd (NASDAQ:VBLT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Vascular Biogenics Ltd (NASDAQ:VBLT)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Vascular Biogenics Ltd (NASDAQ:VBLT)
DateHeadline
06/29/16 06:59 PMH.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics
06/28/16 07:00 PMH.C. Wainwright Starts Vascular Biogenics Ltd (VBLT) at Buy - StreetInsider.com
06/28/16 06:07 AMCoverage initiated on VBL Therapeutics by H.C. Wainwright -
06/27/16 06:53 PMHot Stocks: Neuralstem, Inc. (NASDAQ:CUR), Vascular Biogenics Ltd. (NASDAQ:VBLT), Accelerate Diagnostics, Inc ... - KC Register
06/27/16 06:39 AMNext Weeks Broker Price Targets For Vascular Biogenics Ltd. (VBLT) - Fiscal Standard
06/26/16 06:38 AMStrong Sell Calls Recommendations For Vascular Biogenics Ltd. (NASDAQ:VBLT) At 0 - Investor Newswire
06/22/16 06:46 AMVascular Biogenics Ltd. (NASDAQ:VBLT) Analyst Rating Consensus - TheFounders Daily
06/21/16 06:29 AMVascular Biogenics Ltd. (VBLT) Analyst Price Targets For The Coming Week - Fiscal Standard
06/21/16 06:19 AMVBL Therapeutics Announces Appointment of Dr. Rachel W. Humphrey to Head of the Scientific Advisory Board - [at noodls] - TEL AVIV, Israel, June 21, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
06/17/16 09:45 AMVascular Biogenics Ltd. (VBLT) Current Analyst Ratings - Fiscal Standard
06/16/16 11:49 AMVascular Biogenics Ltd. Closes $24 Million Registered Direct Offering - [at noodls] - TEL AVIV, Israel, June 16, 2016 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. ('VBL Therapeutics' or the 'Company') (NASDAQ:VBLT) announced that on June 10, 2016, it closed its previously announced sale ...
06/13/16 10:03 AMStock's Earnings Analysis: STORE Capital Corporation (NYSE:STOR), Vascular Biogenics Ltd. (NASDAQ:VBLT) - Beacon Chronicle
06/10/16 10:12 AMInvestors Focused Stocks: Array BioPharma Inc. (NASDAQ:ARRY) , Vascular Biogenics Ltd. (NASDAQ:VBLT) - Street Updates
06/09/16 10:12 AMEarnings Analysis to Watch: Brookdale Senior Living Inc. (NYSE:BKD), Vascular Biogenics Ltd. (NASDAQ:VBLT) - Beacon Chronicle
06/08/16 05:02 PMVascular Biogenics Ltd. :VBLT-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/07/16 07:22 PMServices Stocks Try To Grab Potentials- Vascular Biogenics (NASDAQ:VBLT), Array BioPharma (NASDAQ:ARRY) - Seneca Globe
06/07/16 01:42 PM8 Biggest Mid-Day Losers For Tuesday - DryShips Inc. (NASDAQ: DRYS) shares fell 44.07 percent to $1.32 after the company announced that it has breached some financial covenants. The company also said that it has yet to make final balloon installments on three matured banking facilities and three lenders have declared event a default. Vascular Biogenics Ltd (NASDAQ: VBLT) shares fell 12.55 percent to $5.99 after surging 72.54 percent on Monday. The company reported a $24 million registered direct offering. Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares 12.06 percent to $25.37 after ...Full story available on Benzinga.com
06/07/16 09:58 AMWorth Watching Stocks Roundup: Vascular Biogenics Ltd (NASDAQ:VBLT), Gerdau SA (ADR) (NYSE:GGB) - NYSE Journal (press release)
06/07/16 09:58 AMWatch List - Cisco Systems, (NASDAQ:CSCO), Vascular Biogenics, (NASDAQ:VBLT) - Wall Street 24
06/07/16 09:58 AMVascular Biogenics Ltd (NASDAQ:VBLT) & ProNAi Therapeutics (NASDAQ:DNAI) Healthcare Stocks in the News - Wall Street 24
06/07/16 09:58 AMEarnings Overview: Globalstar Inc. (NYSEMKT:GSAT), Vascular Biogenics Ltd. (NASDAQ:VBLT) - Beacon Chronicle
06/07/16 07:18 AMVBL Therapeutics to Present Today at the 2016 BIO International Convention - [at noodls] - Dror Harats, CEO will discuss ASCO newly-reported VB-111 clinical data in Ovarian Cancer and rGBM TEL AVIV, Israel, June 07, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced that Chief ...
06/06/16 07:15 PMVascular Biogenics Surges 80% Off Double Catalyst - Benzinga
06/06/16 12:42 PM9 Biggest Mid-Day Gainers For Monday - Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares jumped 105.5 percent to $2.12 amid news of merger with Zone Technologies. Vascular Biogenics Ltd (NASDAQ: VBLT) shares rose 81.11 percent to $7.19 in pre-market trading after the company reported data that showed significant overall survivor benefit in rGBM patients receiving VB-111 versus historical Avastin. Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) shares climbed 65.15 percent to $7.27 after the company issued updated data from its DNA damage response program on seliciclib and sapacitabine combo in patients with solid ...Full story available on Benzinga.com
06/06/16 11:40 AMVascular Biogenics Ltd (VBLT) Stock Roars Higher on Cancer Trial - <p><a rel="nofollow" href="http://investorplace.com">InvestorPlace</a><a rel="nofollow" href="http://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Vascular Biogenics (VBLT) is soaring in Monday's trading after reporting wonderful Phase I/II trial data for an ovarian cancer treatment.</p> <p>The post <a rel="nofollow" href="http://investorplace.com/2016/06/vascular-biogenics-ltd-vblt-stock/">Vascular Biogenics Ltd (VBLT) Stock Roars Higher on Cancer Trial</a> appeared first on <a rel="nofollow" href="http://investorplace.com">InvestorPlace</a>.</p>
06/06/16 11:15 AMVascular Biogenics Ltd. (VBLT) Is Up Sharply On Study Results - RTT News
06/06/16 10:21 AMHere’s Why These Five Stocks Are Surging Today -
06/06/16 09:59 AMVascular Biogenics (VBLT) Stock Spikes on Positive Trial Results -
06/06/16 07:55 AMWhy Vascular Biogenics Is One of the Biggest Winners From ASCO So Far -
06/06/16 07:40 AMVascular Biogenics stock up 34% in pre-market trade after positive cancer drug trial results -
06/06/16 06:18 AMVB-111 Clinical Data Presented at ASCO Demonstrate Significant Increase in Overall Survival in Platinum-Resistant Ovarian Cancer - [at noodls] - VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose level (810 days vs. 172 days, p=0.042) 60% (9 of 15) durable response rate (as measured by reduction ...
06/03/16 07:50 PMVascular Biogenics Ltd. (VBLT) Is Up On Phase 2 Study Results - RTT News
06/03/16 03:15 PMClinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data - [at noodls] - VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous exposure ...
06/03/16 03:05 PM4:05 pm VBL Therapeutics Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint: Clinical Data Presented at ASCO demonstrate significant overall survival benefit vs. historical Avastin -
06/03/16 10:09 AMStrong Sell Calls Count For Vascular Biogenics Ltd. (NASDAQ:VBLT) At 0 - Investor Newswire
06/02/16 07:38 PMBroker Watchlist: Vascular Biogenics Ltd. (VBLT) - Share Trading News - Broker Watchlist: Vascular Biogenics Ltd. (VBLT)Share Trading News01/22/2015 – Vascular Biogenics Ltd. had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 19 price target on the stock. The share price of Vascular Biogenics Ltd. (VBLT) was up +1.14% during the last trading session, with a ...
05/31/16 08:02 AMStock Review and Earnings Check on Vascular Biogenics Ltd. (NASDAQ:VBLT) - HNN - Stock Review and Earnings Check on Vascular Biogenics Ltd. (NASDAQ:VBLT)HNNCurrently, sell-side analysts are expecting Vascular Biogenics Ltd. (NASDAQ:VBLT) to report quarterly EPS of $-0.2. The company's next earnings report is expected to be published on or around 2016-08-11 for the period ending on 2016-06-30. The company ...and more »
05/30/16 08:59 PMNext Weeks Broker Price Targets For Vascular Biogenics Ltd. (VBLT) - Share Trading News - Next Weeks Broker Price Targets For Vascular Biogenics Ltd. (VBLT)Share Trading NewsVascular Biogenics Ltd. has a 50 day moving average of 3.29 and a 200 day moving average of 3.90. The stock's market capitalization is 81.81M, it has a 52-week low of 2.76 and a 52-week high of 12.25. The share price of the company (VBLT) was down ...How Many Vascular Biogenics Ltd (NASDAQ:VBLT)'s Analysts Are Bearish?HNNall 2 news articles »
05/20/16 04:22 PMEdited Transcript of VBLT earnings conference call or presentation 13-May-16 12:30pm GMT -
05/13/16 08:58 AMVBL Therapeutics Announces First Quarter 2016 Financial Results and Provides Business Update - [at noodls] - TEL AVIV, Israel, May 13, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments ...
05/13/16 07:07 AMVascular Biogenics reports 1Q loss -
05/05/16 03:21 PMVBL Therapeutics to Report First Quarter 2016 Financial Results on May 13 - [at noodls] - TEL AVIV, Israel, May 05, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class ...
05/03/16 10:30 AMVBL Therapeutics Announces Clinical Data to be Presented at 2016 ASCO Annual Meeting - [at noodls] - TEL AVIV, Israel, May 03, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments ...
04/27/16 07:11 AMVBL Therapeutics to Host Key Opinion Leader Meeting on Wednesday, May 4 in New York City - [at noodls] - TEL AVIV, Israel, April 27, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
04/19/16 07:05 AMVBL Therapeutics Announces Publication of NASH Data for Lecinoxoids Molecules VB-201 and VB-703 - [at noodls] - TEL AVIV, Israel, April 19, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
03/29/16 01:43 PMEdited Transcript of VBLT earnings conference call or presentation 29-Mar-16 12:30pm GMT -
02/26/16 11:58 AMHow Analysts Feel About Vascular Biogenics Ltd (NASDAQ:VBLT)? - RiversideGazette.com - How Analysts Feel About Vascular Biogenics Ltd (NASDAQ:VBLT)?RiversideGazette.comOut of 4 analysts covering Vascular Biogenics (NASDAQ:VBLT), 4 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $27.5 is the highest target while $14 is the lowest. The $19.88 average target is 627.94% above today's ($3.4) stock ...
02/26/16 11:58 AMNew Price Targets On Vascular Biogenics Ltd. (VBLT) - Risers & Fallers - New Price Targets On Vascular Biogenics Ltd. (VBLT)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Vascular Biogenics Ltd. (VBLT). The latest broker reports which are currently outstanding on Thursday 25th of February state 0 analysts have a rating of “strong buy”, 4 ...
02/22/16 07:00 AMVBL Therapeutics Announces Launch of the First Israeli Site as Part of the GLOBE International Pivotal Trial for VB-111 - [GlobeNewswire] - TEL AVIV, Israel, Feb. 22, 2016-- VBL Therapeutics, today announced enrollment of the first patient in Israel, as part of the GLOBE Phase 3 pivotal trial for lead candidate VB-111. The trial, which was ...
02/07/16 01:08 PMIs Vascular Biogenics Ltd a Buy? The Stock Rises Again - Sonoran Weekly Review - Is Vascular Biogenics Ltd a Buy? The Stock Rises AgainSonoran Weekly ReviewThe stock of Vascular Biogenics Ltd (NASDAQ:VBLT) is a huge mover today! The stock increased 7.28% or $0.23 on February 5, hitting $3.39. About 123,617 shares traded hands. Vascular Biogenics Ltd (NASDAQ:VBLT) has declined 49.03% since July 1, ...
About Vascular Biogenics Ltd

Vascular Biogenics Ltd logoVascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. The Company is developing VB-111, the lead oncology product candidate from its VTS platform technology, which is a gene-based biologic for the treatment of solid tumor indications, with clinical programs in recurrent glioblastoma (rGBM), thyroid cancer and ovarian cancer. The Company is also conducting a program targeting anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules developed by the Company that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VBLT
  • CUSIP:
Key Metrics:
  • Previous Close: $4.15
  • 50 Day Moving Average: $3.99
  • 200 Day Moving Average: $3.69
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $107.21M
  • Current Quarter EPS Consensus Estimate: $-0.82 EPS
Additional Links:
Vascular Biogenics Ltd (NASDAQ:VBLT) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha